Can arrive at the end of summer day Covid vaccine updated for Omicron . variants – Omicron 5 also comes out on top – from the coronavirus. to announce it modern It demonstrates some promising results from a phase 2/3 study that “met all primary end points” identified for the trial.
50 mcg filter booster Bivalent anti-Covid booster (mRNA-1273.214) “Superior response in terms of antibodies against the Omicron variant of Sars-CoV-2 has been demonstrated, after one month of administration – the pharmaceutical company demonstrates – compared to the original Moderna vaccine (mRNA-1273)”.
“We are pleased to share the preliminary analysis of mRNA-1273.214 data,” which “represents a breakthrough in the fight against Covid,” he explained in a statement. Stefan Bancel, CEO of Moderna. “We provide our raw data and analyzes to the regulatory authorities with Hopefully a bivalent booster containing Omicron will be available in late summer“.
“Given these data — Bancel noted — along with the robustness we saw with our first bivalent enhancer candidate, mRNA-1273.211, we expect durable protection against disturbing variants with mRNA-1273.214, making it Leading Candidate for Fall 2022The director of the US company concludes, “The bivalent booster candidates demonstrate the power of Moderna’s mRna platform in vaccine development in rapid response to global public health threats.”
How does mRNA-1273.214 work
In detail, the Moderna bivalent booster candidate contains an already approved Spikevax* vaccine and a vaccine candidate targeting the Omicron variant. A booster dose of 50 μg of mRNA-1273.214 . was found ‘Overall well tolerated’ in 437 study participantswith side effects similar to a booster dose of mRNA-1273 “the vaccine already used,” at the 50 mcg dose level.
Moderna explains that the criteria for assessing the Excellence of the Enhanced Candidate have been met. An enhanced dose of mRNA-1273.214 increased the geometric mean neutralization titers (Gmt) compared to Omicron by “About 8 times compared to baseline levels”. and “Primary non-inferiority endpoints against SARS-CoV-2 progenitors were also achieved.” Among the negative participants 1 month after dosing, the GMT progenitor against Sars-CoV-2 for the booster candidate was 5,977, compared to the Spikevax Gmt vaccine of 5,649. Against Omicron, the GMT was 2,372 compared to 1473 for the approved vaccine. The binding antibody (Msd) counters were also “significantly higher than all other variants of interest (Alpha, Beta, Gamma, Delta, Omicron) for mRNA-1273.214”.
The results of the beta-containing bivalent enhancer filter, i.e., mRNA-1273.211, announced in April 2022, showed superiority over the Beta, Delta and Omicron variants one month after administration; This was always against the Beta and Omicron variants after 6 months of taking it. “Given the significantly higher antibody titer induced by mRNA-1273.214 compared to mRNA-1273,” Moderna predicts that antibody titer induced by the omicron-directed enhancer, “mRNA-1273.214, They will be more durable over time against Omicron than mRNA-1273Moderna will report data beginning on day 91 after vaccination later in the summer and plans to provide interim analysis and data to regulatory authorities for review in the coming weeks.
In cooperation with Adnkronos
“Food expert. Unapologetic bacon maven. Beer enthusiast. Pop cultureaholic. General travel scholar. Total internet buff.”